Qualyst Inc.
This article was originally published in Start Up
Executive Summary
Qualyst Inc. offers its ADME and toxicology technologies not on a service model, but as a licensing model for technology and transfer to drug developers. The most fully developed of Qualyst's technologies is B-Clear, which it says is the only in vitro model available to industry today that is predictive of in vivo biliary clearance and excretion.
You may also be interested in...
Start-Ups with Predictive ADME/Tox Technologies
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.